The Centers for Medicare & Medicaid Services (CMS) has announced that its temporary program to cover GLP-1 drugs for obesity in Medicare.
In a first, the federal government is allowing certain hemp products to be used as treatments for people on Medicare. The new program, called the Substance Access Beneficiary Engagement Incentive, is ...
The Trump administration decided to put the pilot on hold until at least 2027.
The Centers for Medicare and Medicaid Services (CMS) and the U.S. Food and Drug Administration (FDA) announced on Thursday ...
The BALANCE program was intended to cover weight-loss drugs for Medicaid beneficiaries, but is delayed. A new solution with ...
The Centers for Medicare & Medicaid Services (CMS) will extend its temporary Medicare GLP-1 Bridge program for obesity drug coverage through the end of 2027, delaying the launch of a longer-term model ...
The Centers for Medicare & Medicaid Services announced a seven-prong update to the Civil Money Penalty Reinvestment Program on Monday. The agency has increased the project funding cap by 20% and also ...
The Trump administration will require all 50 states to explain their plans to revalidate some of their Medicaid providers in ...
The Legislative Budget Commission on Tuesday approved two requests from the Agency for Health Care Administration to give it ...
Industry stakeholders left a recent meeting with Centers for Medicare & Medicaid Services (CMS) Administrator Dr. Mehmet Oz ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results